Search

Peptide

Reference library

Educational peptide reference — research use only.

Research & educational use only

For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.

The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.

Survodutide

A GLP-1/glucagon dual agonist studied in obesity and NASH research.

Half-life (approx.)
~days (approx., subQ; phase trials)
Diluent
Bacteriostatic water (0.9% benzyl alcohol)
Common vials
5, 10 mg

Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.

Overview

Survodutide (BI 456906) is a GLP-1/glucagon dual agonist in phase 2 trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Glucagon component adds hepatic fat oxidation to GLP-1-mediated satiety in its research rationale. GLP-1/glucagon dual agonist (BI 456906) in phase 2 obesity and MASH research.

Structure & identity

GLP-1/glucagon dual agonist BI 456906

Status: Investigational.

Mechanism

Survodutide engages GLP-1 and glucagon receptors, combining appetite suppression with hepatic fat oxidation signals in published metabolic research.

GLP-1/glucagon dual agonist combining appetite suppression with hepatic fat oxidation. Glucagon component adds hepatic fat oxidation to GLP-1-mediated satiety signaling.

Studies & clinical programs

  • Phase 2 dual agonist trials(Phase 2)

    Obesity and MASH research populations

    • GLP-1 and glucagon dual agonism studied for weight and hepatic fat endpoints.

Research models in literature

  • Phase 2 obesity trials
  • MASH/NAFLD liver fat MRI studies

Literature highlights

  • GLP-1/glucagon dual agonist (BI 456906) in phase 2 obesity and MASH/NAFLD liver-fat trials.
  • Hepatic fat MRI and weight endpoints combined in metabolic liver-disease research.
  • Investigational — compared with retatrutide and semaglutide in trial landscape reviews.

Key targets & pathways

GLP-1RGCGRLiver fat MRIGlucagon-mediated lipolysis

Research areas

Dual agonistMASH/NASHObesityGlucagon component

Routes in research literature

Subcutaneous

Also known as

BI 456906GLP-1/glucagon dual agonist

Stability & storage phases

PhaseConditionGuidance
LyophilizedSealed vial, refrigerated (2–8 °C)Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial.
ReconstitutedBacteriostatic water (0.9% benzyl alcohol), refrigeratedMost aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date.
Working aliquotsPre-drawn syringes or microtubes, frozen (−20 °C)Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation.

Stability windows are formulation-dependent — verify published data and your lab SOP.

Reconstitution reference table

Vial (mg)Diluent (mL)mcg/mLUnits @ 100 mcgUnits @ 250 mcgUnits @ 500 mcg
522500.041020
1025000.02510

U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.

Reconstitution steps

  1. Allow vial to reach room temperature (15–30 min)
  2. Swab rubber stopper with alcohol prep pad
  3. Draw calculated bacteriostatic water into syringe
  4. Inject diluent slowly down vial wall — do not spray directly onto cake
  5. Gently swirl until fully dissolved — do not shake vigorously
  6. Label with date, concentration, and diluent volume
  7. Refrigerate and use within your lab stability window

Reconstituted per research protocol.

Laboratory record checklist

  • Compound identity recorded in lab notebook (name, lot, preparation date)
  • Analytical identity cross-checked against published sequence or structure
  • Potency or concentration documented from analytical certificate when available
  • Purity or HPLC data filed when provided with research material
  • Appearance noted: intact lyophilized cake or uniform powder
  • Sterility / endotoxin report archived when available
  • Storage temperature applied immediately per published stability guidance